<DOC>
	<DOCNO>NCT01094535</DOCNO>
	<brief_summary>The aim study determine whether secretin-enhanced MRCP ( S-MRCP ) well traditional magnetic resonance imaging ( MRI ) pancreas allow investigator quantify pancreas ' ability secrete hormone well digestive enzyme , surgery . The investigator hypothesize S-MRCP provide novel non-invasive measure pancreatic function .</brief_summary>
	<brief_title>Secretin-enhanced Magnetic Resonance Cholangiopancreatography ( S-MRCP ) Pancreatic Function Following Surgery</brief_title>
	<detailed_description>Surgical resection offer hope cure pancreatic adenocarcinoma . While perioperative mortality rate decline recent year , pancreatectomy still associate significant postoperative malnutrition , maldigestion , glucose intolerance , mostly result pancreatic insufficiency . Quantifying residual pancreatic function remain challenge , essential improve survival quality life pancreatic cancer patient . Secretin-enhanced magnetic resonance cholangiopancreatography ( S-MRCP ) recently emerge widely-accepted noninvasive technique assess morphological change pancreatic duct , well functional secretory capacity gland . The aim study evaluate S-MRCP mean assess pancreatic reserve patient undergoing surgical resection pancreatic carcinoma . As adjunct S-MRCP , also evaluate concomitant use dynamic MRI contrast enhancement . This prospective study twelve patient undergo S-MRCP/MRI within 30 day surgery 3 , 6 , 12 month post-operatively . Quantitative analysis S-MRCP include pancreatic duct diameter volume secretin administration . MRI analyze mean T1 signal intensity , total parenchymal volume , gadolinium enhancement . These radiological parameter compare clinical parameter exocrine function ( subjective reporting steatorrhea abdominal pain well level fecal elastase1 fat soluble vitamin stool sample ) well endocrine function ( fast blood glucose , hemoglobin A1c , amylin , glucagon , somatostatin level , well arginine-stimulated level islet cell hormone ) .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Secretin</mesh_term>
	<criteria>18 year age old . Tissueconfirmed diagnosis pancreatic adenocarcinoma . Scheduled surgical resection adenocarcinoma ( Whipple distal pancreatectomy ) . Able give inform consent History radiation therapy abdomen prior surgery . Any contraindication MRI , include limited implanted metal device ( e.g . pacemaker , berry aneurysm clip , neural stimulator , cochlear implant , metal eye ) . Treatment investigational drug within 1 month prior day study drug administration . Current enrollment interventional study . Creatinine great 2.0 . Significant liver disease , liver mass , evidence portal hypertension . Pregnancy . History sensitivity secretin . Unwilling unable sign inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Pancreatic adenocarcinoma</keyword>
	<keyword>Synthetic human secretin</keyword>
	<keyword>Secretin-enhanced MRCP</keyword>
	<keyword>Pancreatic insufficiency</keyword>
	<keyword>Endoscopic Pancreatic Function Test ( ePFT )</keyword>
	<keyword>Endocrine pancreatic function test</keyword>
	<keyword>Exocrine pancreatic function test</keyword>
</DOC>